Research applications

In response to the coronavirus outbreak, CPRD is expediting processing of protocols relating to COVID-19 research. To ascertain whether your protocol is eligible for rapid review please email isac@cprd.com before you submit your application and include a clear impact statement in terms of public health, safety or policy. To understand how the current situation may impact on data processing and access requests see here

To help coordinate activities and avoid duplication of research effort, see information on COVID-19 studies underway. Find out more about the COVID-19 data included in the CPRD primary care databases.

Access to CPRD data is subject to protocol approval by an Independent Scientific Advisory Committee (ISAC). Approval is required if access to anonymised patient level data is being requested for research purposes.

This includes access to the following:

For further clarifications please contact the ISAC Secretariat at isac@cprd.com

View the list of approved studies using CPRD data.

Research protocols

All protocols must be submitted via the Electronic Research Applications Portal (eRAP) at www.erap.cprd.com. Applicants, and all members of the research team, need an approved eRAP account in order to submit an application.

The eRAP system replaces the old application form, which can be found below for reference.

(PDF,158KB, 6 pages)

(PDF, 347KB, 15 pages)   

Privacy notice

We will use personal data provided as part of an application for studies using CPRD data, both to arrange, support, and control use of that information under contract or licence and to vet applications for access to CPRD and related data (particularly CVs and past experience for chief and principal investigators). Please look here for more information about your legal rights and how to complain to the Information Commissioner’s Office.

Resubmissions and amendments 

All protocol applications and resubmissions are to be made on eRAP (www.erap.cprd.com). The ability to submit amendments to approved protocols is not yet available via eRAP. We ask that applicants who wish to submit an amendment to an existing protocol discuss this with the ISAC Secretariat by emailing isac@cprd.com. Please do not submit amended protocol documents to ISAC by email. Amendments submitted via email will not be sent for review. 

Feasibility studies

Applicants wishing to submit a Feasibility Study must contact isac@cprd.com to discuss the study prior to submitting an application. Feasibility study applications must be submitted to the ISAC Secretariat using the Feasibility Studies Application Form. Applications will not be accepted in any other format. In addition, a brief curriculum vitae (CV) and conflict of interest statement for each researcher named on the application should be included.

The Feasibility Study Application Form, Application Guidance Notes, and CV template can be downloaded below.

Completed Feasibility Study applications should be sent to the ISAC Secretariat at enquiries@cprd.com

The Secretariat will provide a Feasibility Study number for use in future communications.  

 (Word, 301KB, 4 pages) 

(Word, 37KB, 1 page)

(PDF, 233KB, 9 pages)

Exemptions

Some uses of data, such as conducting analyses for submissions to regulatory bodies, are exempt from ISAC review. 

Analysis for regulatory bodies 

In general, ISAC approval is required prior to release of CPRD data to any third party, so as to ensure that the standard of studies carried out using CPRD data is maintained. However, there are some types of aggregate data necessary for regulatory work that is suitable for exemption from this requirement, such as:

  • Counts of patients receiving prescriptions for a certain substance;
  • Counts of prescriptions for a certain substance / substances;
  • Distribution of number of prescriptions per patient (mean, median, minimum, maximum, interquartile range etc…);
  • Distribution of prescription duration;
  • Distribution of patient time at risk;
  • Counts of patients with a particular clinical event. 


[Page last reviewed 8 October 2020]